HCVプロテアーゼ

シグナル伝達経路

研究分野

  • 阻害剤の選択性比較
  • 溶解度
カタログ番号 製品カタログ 溶解度(25°C)
DMSO アルコール
S1482 Daclatasvir (BMS-790052) <1 mg/mL 148 mg/mL 148 mg/mL
S1538 Telaprevir (VX-950) <1 mg/mL 136 mg/mL <1 mg/mL
S1480 Lomibuvir (VX-222, VCH-222) <1 mg/mL 89 mg/mL 89 mg/mL
S1183 Danoprevir (ITMN-191) <1 mg/mL 144 mg/mL 144 mg/mL
S3728 Grazoprevir <1 mg/mL 100 mg/mL 100 mg/mL
S3733 Boceprevir <1 mg/mL 100 mg/mL 100 mg/mL
S3724 Velpatasvir 100 mg/mL 100 mg/mL 100 mg/mL
S7579 Ledipasvir (GS5885) <1 mg/mL 100 mg/mL 100 mg/mL
製品コード 製品説明 文献中の使用例 お客様のフィードバック
S1482

Daclatasvir (BMS-790052)

Daclatasvir (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.

S1538

Telaprevir (VX-950)

Telaprevir (VX-950) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.

S1480

Lomibuvir (VX-222, VCH-222)

Lomibuvir (VX-222, VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2.

S1183

Danoprevir (ITMN-191)

Danoprevir(ITMN-191) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.

S3728

Grazoprevir

Grazoprevir anhydrous is a Hepatitis C Virus NS3/4A Protease inhibitor with IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively.

S3733

Boceprevir

S3724

Velpatasvir

Velpatasvir is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.

S7579

Ledipasvir (GS5885)

Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

Tags: HCV protease treatment | HCV protease assay | HCV protease inhibitors review